Summary

Japan Kidney Cancer Drugs Market was valued at USD 210.23 Million in 2024 and expected to reach USD 296.24 Million by 2030 with a CAGR of 5.84% during the forecast period. The Japan kidney cancer drugs market is primarily driven by the rising incidence of renal cell carcinoma (RCC) and advancements in targeted therapies and immunotherapies. As the prevalence of kidney cancer increases, fueled by factors such as an aging population and lifestyle-related risk factors, there is a growing demand for effective treatment options. Innovations in drug development, including the introduction of new targeted therapies and immune checkpoint inhibitors, offer improved efficacy and personalized treatment approaches, contributing to market growth. Supportive healthcare policies and increased healthcare expenditure in Japan further enhance access to advanced treatments. The combined impact of these factors underscores the robust expansion of the Japan Kidney Cancer Drugs Market.
Key Market Drivers
Rising Incidence of Kidney Cancer
The rising incidence of kidney cancer, particularly renal cell carcinoma (RCC), is a crucial driver behind the growth of the Japan kidney cancer drugs market. Japan has experienced a steady increase in kidney cancer cases over recent years, influenced by several factors including an aging population and lifestyle-related risk factors such as smoking, obesity, and hypertension. This upward trend in cancer diagnoses has expanded the patient population, intensifying the need for effective and innovative treatment options.
The demographic shift towards an older population in Japan has contributed significantly to the rise in kidney cancer cases. Older adults are at a higher risk for various cancers, including RCC, due to age-related changes in cellular processes and accumulated exposure to risk factors over time. Lifestyle factors prevalent in modern Japanese society, such as increased rates of smoking and rising obesity levels, have further exacerbated the incidence of kidney cancer. Hypertension, another significant risk factor, is common among the elderly and contributes to the development and progression of kidney cancer.
This increasing prevalence of kidney cancer has led to heightened demand for advanced drug therapies that can effectively manage both early-stage and advanced forms of the disease. Early diagnosis and treatment are essential for improving patient outcomes, as they allow for more targeted and potentially curative interventions. The expanding patient base has driven healthcare providers to seek out more effective and precise treatments to address the growing burden of kidney cancer. In response to this demand, pharmaceutical companies are increasingly focusing on developing and commercializing novel therapies. The market is seeing a surge in the introduction of innovative drug treatments, including targeted therapies and immunotherapies, designed to address the specific genetic and molecular characteristics of RCC. These advancements are aimed at improving the efficacy of treatment regimens, reducing side effects, and ultimately enhancing patient survival rates. The need for effective treatment options has also led to significant investment in research and development (R&D) within the pharmaceutical industry. Companies are conducting extensive clinical trials to explore new drug formulations and combinations that offer improved outcomes for kidney cancer patients. The drive for innovation is supported by advancements in medical technology and a deeper understanding of the molecular mechanisms underlying RCC, which are enabling the development of more personalized and targeted therapies.
Advancements in Targeted Therapies
Advancements in targeted therapies have profoundly influenced the Japan kidney cancer drugs market by introducing a more precise and personalized approach to treatment. Unlike traditional chemotherapy, which broadly targets rapidly dividing cells and can affect both cancerous and healthy tissues, targeted therapies are designed to address specific molecular targets associated with cancer. This targeted approach enhances the efficacy of treatment while minimizing collateral damage to normal cells, thereby reducing side effects and improving patient quality of life. One of the most significant advancements in targeted therapies for kidney cancer is the development of tyrosine kinase inhibitors (TKIs). TKIs work by blocking the action of tyrosine kinases, which are enzymes involved in the signaling pathways that promote tumor cell growth and survival. In kidney cancer, these inhibitors target specific proteins, such as the vascular endothelial growth factor (VEGF) receptor, which plays a crucial role in tumor angiogenesis—the formation of new blood vessels that supply nutrients to the tumor. By inhibiting these pathways, TKIs effectively starve the tumor of necessary resources, slowing its growth and potentially leading to tumor shrinkage. In August 2021, Ono Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. announced that they have received approval for a combination therapy involving ONO's Opdivo® (nivolumab) Intravenous Infusion, a human anti-human PD-1 monoclonal antibody, and Takeda's CABOMETYX® (cabozantinib s-malate) tablets. CABOMETYX is a tyrosine kinase inhibitor licensed from Exelixis, Inc. for development and commercialization in Japan. This approval marks a partial change in the approved indications for these drugs, allowing their combined use in treating unresectable or metastatic renal cell carcinoma (RCC).
VEGF inhibitors represent another critical advancement in targeted kidney cancer therapies. These drugs specifically target the VEGF protein or its receptors to prevent the formation of new blood vessels that tumors need to grow and spread. By blocking VEGF signaling, these inhibitors can reduce tumor vascularization, limit tumor growth, and enhance the effectiveness of other treatments. The introduction of VEGF inhibitors has been a game-changer for patients with advanced kidney cancer, offering a more focused and effective approach compared to traditional chemotherapy. The continuous innovation in targeted therapies has led to the approval of several new drugs in Japan, further driving market growth. The development pipeline for kidney cancer drugs includes several promising candidates that aim to improve upon existing treatments. This ongoing innovation is fueled by advances in molecular biology, genetic research, and a deeper understanding of the mechanisms underlying kidney cancer. As researchers identify new molecular targets and develop drugs that can more precisely interact with these targets, the range of available therapies expands, offering more options for personalized treatment.
Emergence of Immunotherapies
The rise of immunotherapies represents a significant driver of the Japan kidney cancer drugs market, bringing a transformative approach to treating kidney cancer. Immunotherapy harnesses the power of the body’s own immune system to target and eliminate cancer cells, offering a novel and highly promising alternative to conventional treatments. This therapeutic strategy focuses on enhancing the immune system’s ability to recognize and attack cancer cells more effectively. One of the most notable advances in immunotherapy for kidney cancer is the development of immune checkpoint inhibitors. These drugs work by blocking specific proteins on cancer cells or immune cells that would normally inhibit the immune response. In the case of advanced renal cell carcinoma (RCC), immune checkpoint inhibitors targeting proteins such as PD-1 (Programmed Death-1) and PD-L1 (Programmed Death-Ligand 1) have demonstrated remarkable efficacy. PD-1 and PD-L1 are immune checkpoint proteins that cancer cells exploit to evade detection and destruction by the immune system. By inhibiting these proteins, the drugs essentially release the brakes on the immune system, allowing it to attack and kill cancer cells more effectively.
The approval of these immune checkpoint inhibitors in Japan has been a game-changer for the kidney cancer treatment landscape. Clinical trials have shown that these therapies can lead to significant improvements in patient outcomes, including enhanced overall survival rates and longer progression-free survival compared to traditional treatments. These promising results have generated considerable excitement and optimism in the medical community, as these therapies offer new hope for patients with advanced or refractory kidney cancer who have limited treatment options. The success of immune checkpoint inhibitors in clinical settings has not only expanded the treatment options available for kidney cancer but has also driven substantial growth in the market for kidney cancer drugs. As more patients and healthcare providers become aware of the benefits of immunotherapy, the demand for these innovative treatments continues to rise. This increased demand is further supported by ongoing research and development efforts aimed at refining and expanding immunotherapeutic options.
Growing Focus on Personalized Medicine
The growing emphasis on personalized medicine is significantly shaping the Japan kidney cancer drugs market by promoting more tailored and effective treatment strategies. Personalized medicine focuses on customizing healthcare treatments based on individual patient characteristics, such as genetic profiles, tumor mutations, and molecular markers. This approach enables healthcare providers to design treatment plans that are specifically suited to each patient's unique biological makeup, thereby enhancing the precision and efficacy of cancer therapies. In February 2022, Eisai Co., Ltd. and Merck & Co., Inc., based in Kenilworth, N.J., U.S.A. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, an oral multiple receptor tyrosine kinase inhibitor developed by Eisai, with KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of radically unresectable or metastatic renal cell carcinoma (RCC). This combination is also approved in the U.S. and Europe for first-line treatment of adult patients with advanced RCC. This marks the second approval of LENVIMA plus KEYTRUDA in Japan, following its December 2021 approval for unresectable, advanced or recurrent endometrial carcinoma that progressed after chemotherapy.
In the realm of kidney cancer treatment, personalized medicine has gained momentum due to advances in genomics and biomarker research. The sequencing of cancer genomes has revealed specific genetic mutations and molecular targets that drive tumor growth in renal cell carcinoma (RCC). For instance, mutations in genes such as VHL (Von Hippel-Lindau) and alterations in signaling pathways like the mTOR (mechanistic target of rapamycin) pathway are known to play critical roles in kidney cancer progression. Understanding these genetic alterations has led to the development of targeted therapies that can specifically address these mutations and pathways, offering a more focused approach compared to traditional treatments. The advent of targeted therapies is a direct outcome of this personalized approach. Drugs such as tyrosine kinase inhibitors (TKIs) and vascular endothelial growth factor (VEGF) inhibitors have been developed to specifically inhibit the growth and spread of kidney cancer cells by targeting the molecular pathways identified through genomic research. For example, TKIs like sunitinib and sorafenib inhibit multiple tyrosine kinases involved in tumor growth and angiogenesis, while VEGF inhibitors such as bevacizumab block the VEGF pathway, which is crucial for tumor blood vessel formation. These therapies represent a shift towards precision treatment, tailored to the molecular profile of the tumor and the patient’s individual characteristics.
Key Market Challenges
High Costs of Innovative Treatments
One of the major challenges facing the Japan kidney cancer drugs market is the high cost of innovative treatments. While advancements in drug development, such as targeted therapies and immunotherapies, have significantly improved treatment outcomes for kidney cancer patients, these new therapies often come with a substantial price tag. The development and production of cutting-edge drugs involve extensive research and development (R&D) expenses, high manufacturing costs, and regulatory compliance, which contribute to the overall cost of the final product. This high cost can pose significant financial burdens on healthcare systems, patients, and insurance providers. In Japan, despite the government's efforts to make cancer treatments accessible through its universal health insurance system, the high cost of innovative kidney cancer drugs can still result in limitations on coverage and reimbursement. This creates disparities in access to these advanced treatments and may affect patient outcomes, as those who cannot afford these high-cost therapies may have fewer treatment options available. Addressing the challenge of high drug costs requires ongoing dialogue between pharmaceutical companies, healthcare providers, and policymakers to find sustainable solutions that ensure equitable access to life-saving treatments while managing financial pressures on the healthcare system.
Regulatory and Approval Hurdles
Regulatory and approval hurdles present significant challenges in the Japan kidney cancer drugs market. The process of bringing new drugs to market in Japan involves rigorous evaluation by regulatory authorities, including the Pharmaceuticals and Medical Devices Agency (PMDA). The approval process requires comprehensive clinical trial data demonstrating the safety and efficacy of new treatments. While this thorough evaluation ensures high standards for drug safety and effectiveness, it can also lead to delays in market entry. The need for extensive clinical trials, which often involve multiple phases and significant resources, can be a barrier for pharmaceutical companies, particularly smaller firms or those with limited R&D budgets. The Japanese regulatory environment is known for its strict requirements and lengthy approval timelines, which can slow down the introduction of innovative therapies. These regulatory challenges can impact the timely availability of new kidney cancer drugs, affecting patient access to the latest treatment options. To mitigate these challenges, pharmaceutical companies must navigate the regulatory landscape carefully, collaborate with local experts, and prepare for potential delays in the drug approval process.
Key Market Trends
Advancements in Drug Formulations and Delivery Systems
Advancements in drug formulations and delivery systems are significantly propelling the growth of the Japan kidney cancer drugs market by enhancing the efficacy and patient experience of treatments. Innovations in drug delivery technologies have been pivotal in improving the management of kidney cancer, focusing on optimizing how medications are administered to ensure better therapeutic outcomes and greater patient compliance.
One major area of advancement is the development of improved oral formulations. Traditionally, many cancer drugs required intravenous administration, which can be cumbersome and inconvenient for patients. Recent innovations have led to the creation of oral formulations with enhanced bioavailability and stability. These advancements ensure that oral drugs are absorbed more efficiently into the bloodstream and maintain their effectiveness over longer periods. For example, new oral formulations of tyrosine kinase inhibitors (TKIs) and other targeted therapies offer patients a more convenient alternative to intravenous treatments, thereby improving adherence to therapy and overall quality of life.
Extended-release systems represent another significant advancement. These systems are designed to release the drug slowly over an extended period, which helps to maintain consistent drug levels in the bloodstream. This approach can improve the efficacy of treatment by providing a steady therapeutic effect and reducing the frequency of dosing. Extended-release formulations can also minimize peak-and-trough fluctuations in drug levels, which can enhance both efficacy and safety by reducing the likelihood of side effects associated with high drug concentrations. Targeted delivery mechanisms are also revolutionizing the treatment landscape for kidney cancer. These systems aim to deliver drugs directly to the cancer cells or specific tissues, thereby maximizing therapeutic effects while minimizing systemic exposure and adverse effects. Techniques such as nanoparticle-based delivery systems, conjugation with targeting ligands, and localized delivery methods are examples of how targeted delivery can enhance treatment outcomes. For instance, drug-loaded nanoparticles can be engineered to bind specifically to cancer cells, ensuring that the therapeutic agents are delivered precisely where they are needed, thereby improving efficacy and reducing collateral damage to healthy tissues.
Increased Investment in Drug Development
Increased investment in drug development is a pivotal driver of the Japan kidney cancer drugs market, significantly shaping its growth trajectory. Pharmaceutical companies are channeling substantial resources into research and development (R&D) to discover and commercialize new therapies for kidney cancer. This financial commitment is essential for fostering innovation and advancing the treatment landscape for renal cell carcinoma (RCC) and other forms of kidney cancer. The process of developing new drugs is both complex and costly, involving extensive research, clinical trials, and regulatory approvals. To bring a new kidney cancer drug to market, companies must navigate these intricate steps, which require substantial financial backing. Increased investment supports every phase of drug development, from initial discovery and preclinical studies to clinical trials and market launch. This investment is crucial for exploring novel therapeutic approaches, such as targeted therapies and immunotherapies, which hold the potential to address significant unmet medical needs in kidney cancer treatment.
Pharmaceutical companies are particularly focused on developing targeted therapies and immunotherapies due to their potential to revolutionize kidney cancer treatment. Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and vascular endothelial growth factor (VEGF) inhibitors, work by specifically targeting molecular pathways involved in tumor growth, offering more precise and effective treatment options compared to traditional therapies. Immunotherapies, including immune checkpoint inhibitors, harness the body's immune system to fight cancer cells, providing promising new avenues for treating advanced and refractory cases of kidney cancer. The pursuit of these innovative treatments necessitates significant R&D investment to understand the underlying mechanisms of kidney cancer and to develop drugs that can effectively target these mechanisms. The competitive landscape of the kidney cancer drug market further fuels investment in drug development. As more companies enter the market, they are motivated to differentiate themselves by developing cutting-edge therapies and improving existing treatments. This competitive environment drives innovation and encourages companies to invest in new drug research to gain a competitive edge. The introduction of new and effective drugs not only expands the market but also enhances the treatment options available to patients, leading to better clinical outcomes and improved quality of life.
Segmental Insights
Therapy Insights
Based on the Therapy, targeted therapy is currently the dominant approach among immunotherapy, chemotherapy, and targeted therapy. The shift towards targeted therapies reflects significant advancements in the understanding of kidney cancer biology and the development of more precise treatment options. Targeted therapy has gained prominence due to its ability to specifically address the molecular pathways and genetic mutations involved in renal cell carcinoma (RCC), the most common type of kidney cancer. These therapies work by targeting particular molecules or proteins that are crucial for cancer cell growth and survival, thus offering a more tailored and effective treatment compared to traditional methods. Notable examples include tyrosine kinase inhibitors (TKIs) such as sunitinib, sorafenib, and cabozantinib, and vascular endothelial growth factor (VEGF) inhibitors like bevacizumab. These drugs specifically inhibit the pathways that promote tumor angiogenesis (the formation of new blood vessels that supply the tumor) and cellular proliferation, thereby slowing down or stopping the growth of the cancer. The precision of these therapies often leads to better outcomes and fewer side effects compared to traditional chemotherapy.
In contrast, chemotherapy has historically been a cornerstone of cancer treatment but is less commonly used for kidney cancer due to its lower efficacy in this specific context. Traditional chemotherapy targets rapidly dividing cells, but RCC often does not respond well to this approach because its growth is driven more by specific molecular signals rather than by uncontrolled cell division. As a result, chemotherapy has largely been replaced by targeted therapies and immunotherapies in the treatment of kidney cancer. The limited role of chemotherapy in this setting is reflected in its declining market share compared to targeted therapies.
Drug Class Insights
Based on Drug Class, angiogenesis inhibitors are currently the dominant class among monoclonal antibodies, angiogenesis inhibitors, and mTOR inhibitors. The focus on angiogenesis inhibitors reflects their critical role in the management of renal cell carcinoma (RCC), the most prevalent form of kidney cancer. Angiogenesis inhibitors are a major therapeutic class because they specifically target the blood vessels that supply tumors, which is a key mechanism in RCC. Angiogenesis, the process through which tumors develop new blood vessels, is crucial for tumor growth and metastasis. By inhibiting this process, these drugs effectively starve tumors of the nutrients and oxygen they need to grow.
Prominent examples of angiogenesis inhibitors include drugs such as sunitinib, sorafenib, and cabozantinib. These medications are designed to inhibit vascular endothelial growth factor (VEGF) and its receptors, which are pivotal in the formation of new blood vessels. By blocking these signals, angiogenesis inhibitors prevent the tumor from developing a supportive blood supply, thereby slowing its growth and reducing its spread. The dominance of angiogenesis inhibitors in the Japan Kidney Cancer Drugs Market can be attributed to several factors. These drugs have been extensively studied and validated in clinical trials. For instance, sunitinib and sorafenib have shown significant efficacy in improving patient outcomes in RCC, leading to their widespread adoption in clinical practice. The proven effectiveness of these drugs in prolonging survival and managing advanced stages of RCC contributes significantly to their market dominance.
Regional Insights
In the Japan kidney cancer drugs market, the Kanto region stand out as the dominated area. The Kanto region, which includes Tokyo and its surrounding prefectures such as Kanagawa, Chiba, and Saitama, is a significant hub for healthcare and pharmaceutical activities in Japan. This dominance can be attributed to several key factors that make the Kanto region the leading player in the market. Kanto's substantial population base plays a crucial role in its dominance. With Tokyo as Japan's largest city and a major metropolitan area, the Kanto region has a high population density and a large number of patients diagnosed with kidney cancer. This extensive patient pool drives the demand for kidney cancer drugs and creates a robust market for pharmaceutical companies to address. The high number of cases translates to a higher volume of drug prescriptions and treatments, contributing to the region’s market dominance.
The Kanto region is home to many of Japan's leading medical institutions and research centers. Hospitals and clinics in Tokyo and its neighboring prefectures are renowned for their advanced healthcare services and pioneering research in oncology. Institutions like the University of Tokyo Hospital and Keio University Hospital are at the forefront of clinical trials and studies related to kidney cancer treatments. Their involvement in cutting-edge research and development of new therapies accelerates the introduction and adoption of innovative drugs in the market. The presence of these prominent medical centers fosters an environment conducive to the rapid deployment of new kidney cancer therapies. The Kanto region benefits from its concentration of pharmaceutical companies and biotechnology firms. Major drug manufacturers and biotech companies have established their headquarters or significant operations in Tokyo and the surrounding areas. This concentration of industry leaders enhances the region's ability to develop, test, and market new kidney cancer drugs efficiently. Companies based in Kanto are often involved in both domestic and international drug development activities, further strengthening the region's position in the Japan Kidney Cancer Drugs Market.
Key Market Players
• Novartis Pharma K.K.
• AbbVie GK
• Janssen Pharmaceuticals K.K.
• Asahi Kasei Pharma Corporation
• Sun Pharma Japan Limited
• Kyowa Pharmaceutical Industry Co., Ltd.
• Santen Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Senju Pharmaceutical Co., Ltd.
• Taisho Pharmaceutical Co., Ltd.
Report Scope:
In this report, the Japan Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Japan Kidney Cancer Drugs Market, By Therapy:
o Immunotherapy
o Chemotherapy
o Targeted Therapy
• Japan Kidney Cancer Drugs Market, By Drug Class:
o Monoclonal antibodies
o Angiogenesis
o mTOR Inhibitors
• Japan Kidney Cancer Drugs Market, By Route of Administration:
o Oral
o Intravenous
o Subcutaneous
• Japan Kidney Cancer Drugs Market, By Distribution Channel:
o Hospitals
o Retail Pharmacies
o Others
• Japan Kidney Cancer Drugs Market, By Region:
o Hokkaido
o Tohoku
o Kanto
o Chubu
o Kansai
o Chugoku
o Shikoku
o Kyushu
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Japan Kidney Cancer Drugs Market.
Available Customizations:
Japan Kidney Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Japan Kidney Cancer Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapy (Immunotherapy, Chemotherapy, Targeted Therapy)
5.2.2. By Drug Class (Monoclonal antibodies, Angiogenesis and mTOR Inhibitors)
5.2.3. By Route of Administration (Oral, Intravenous and Subcutaneous)
5.2.4. By Distribution Channel (Hospitals, Retail Pharmacies, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. Hokkaido Kidney Cancer Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy
6.2.2. By Drug Class
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
7. Tohoku Kidney Cancer Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy
7.2.2. By Drug Class
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
8. Kanto Kidney Cancer Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy
8.2.2. By Drug Class
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
9. Chubu Kidney Cancer Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
10. Kansai Kidney Cancer Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
11. Chugoku Kidney Cancer Drugs Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapy
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
12. Shikoku Kidney Cancer Drugs Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Therapy
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
13. Kyushu Kidney Cancer Drugs Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Therapy
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
15.1. Merger & Acquisition (If Any)
15.2. Product Launches (If Any)
15.3. Recent Developments
16. Japan Kidney Cancer Drugs Market: SWOT Analysis
17. Porter’s Five Forces Analysis
17.1. Competition in the Industry
17.2. Potential of New Entrants
17.3. Power of Suppliers
17.4. Power of Customers
17.5. Threat of Substitute Products
18. Competitive Landscape
18.1. Novartis Pharma K.K.
18.1.1. Business Overview
18.1.2. Company Snapshot
18.1.3. Products & Services
18.1.4. Financials (As Reported)
18.1.5. Recent Developments
18.1.6. Key Personnel Details
18.1.7. SWOT Analysis
18.2. AbbVie GK
18.3. Janssen Pharmaceuticals K.K.
18.4. Asahi Kasei Pharma Corporation
18.5. Sun Pharma Japan Limited
18.6. Kyowa Pharmaceutical Industry Co., Ltd.
18.7. Santen Pharmaceutical Co., Ltd.
18.8. Otsuka Pharmaceutical Co., Ltd.
18.9. Senju Pharmaceutical Co., Ltd.
18.10. Taisho Pharmaceutical Co., Ltd.
19. Strategic Recommendations
20. About Us & Disclaimer